Table 3.

Effect of each parameter on PFS according to baseline values and to the variation between T1 value (after 1 month of therapy) and T0 value (baseline value). This difference has been indicated as delta value (Δ)

Parameter			Univariate				Two-variable				Multivariablea
Variable	Timepoint	Value	p	HR	Lower HR	Upper HR	p	HR	Lower HR	Upper HR	p	HR	Lower HR	Upper HR
Platelets	Basal	+ 10,000					0.419	1.007	0.900	1.025	–	–	–	–
	Δ	Ref ≤ 25,000					0.039	1.398	1.016	1.922	0.116	1.310	0.935	1.836
White blood cell count	Basal	+ 100					0.001	1.006	1.002	1.010	0.069	0.990	0.979	1.001
	Δ	Ref ≤ 1920					< 0.001	2.063	1.396	3.049	–	–	–	–
Neutrophils	Basal	+ 100					< 0.001	1.011	1.007	1.015	0.003	1.022	1.008	1.037
	Δ	Ref ≤ 310					0.020	1.429	1.058	1.930	–	–	–	–
Lymphocytes	Basal	+ 100					0.054	0.981	0.962	1.000	–	–	–	–
	Δ	Ref ≥ -300					< 0.001	1.910	1.356	2.692	–	–	–	–
NL ratio	Basal	+ 1					< 0.001	1.176	1.078	1.284	–	–	–	–
	Δ	Ref ≤ 0.86					< 0.001	1.975	1.411	2.764	0.004	1.709	1.183	2.468
PL ratio	Basal	+ 1					0.156	1.001	0.999	1.003	–	–	–	–
	Δ	Ref ≤ 22.85					0.001	1.693	1.240	2.311	–	–	–	–
Age	Basal	+ 1	0.210	1.007	0.996	1.019					–	–	–	–
Sex	Basal	Ref F	0.601	0.923	0.682	1.248					–	–	–	–
Number of metastatic sites	Basal	Ref ≥ 3	0.013	0.686	0.509	0.925					–	–	–	–
LDH	Basal	Ref elevated	0.001	0.581	0.420	0.803					0.070	0.729	0.518	1.026

Statistically significant values in bold

At the Δ timepoint the variables have been dichotomized and the “value” represents the reference category

HR (hazard ratio) values are expressed in terms of risk of progression

^aAfter stepwise selection